DHSC outlines priorities for transforming life sciences in UK post coronavirus (COVID-19)

DHSC outlines priorities for transforming life sciences in UK post coronavirus (COVID-19)

The Secretary of State for Health and Social Care, Matt Hancock, has given a speech at the Association of the British Pharmaceutical Industry annual conference, outlining the Department of Health and Social Care’s ambition to transform the UK into a ‘life sciences superpower’. Hancock thanked the life sciences industry for their contribution to tackling the coronavirus (COVID-19) pandemic and set out proposals for how the UK can build back better. Hancock emphasised the importance of antivirals, particularly in providing treatment for people early on and acting as a precautionary measure in settings where someone has tested positive for coronavirus, and has announced the launch of the antivirals taskforce. The mission of the taskforce includes searching for the ‘most promising new drugs’, speeding up their development and manufacture in the UK, and reaching the goal of being able to take antivirals at home where a positive coronavirus test is confirmed.

Hancock set out a number of other priorities for the industry:

• modernising research and regulation, ensuring women’s voices are heard

• supporting the National Institute for Health Research’s Clinical Research Network in recovery of non-coronavirus related studies

• supporting UK life sciences companies through the Life Sciences Investment Programme

• investing in people, particularly encouraging children to take up STEM subjects

• scaling up manufacturing capabilities in the UK

• launching the genome UK Implementation Plan

• investing £20m into the new data-driven Find, Recruit, and Follow-up service for clinical trials

Source: Transforming the UK into a life sciences superpower

Related Articles:
Latest Articles: